- Home
- LSTA
as of 12-16-2025 1:31pm EST
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | BASKING RIDGE |
| Market Cap: | 20.9M | IPO Year: | N/A |
| Target Price: | $23.50 | AVG Volume (30 days): | 23.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.81 - $4.20 | Next Earning Date: | 11-06-2025 |
| Revenue: | $1,070,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -92.86% | Revenue Growth (next year): | N/A |
Compare LSTA vs Leading Stocks
See how LSTA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "LSTA Lisata Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.